2020. június 23., kedd 17:27 |
IgNova files patent application on antibody against COVID-19 |
|
Visbek, June 23, 2020 (APA/OTS) - IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (IgY). |
The patented IgY binds the spike protein of SARS-CoV-2, neutralizing
the virus when it enters the mouth or nose and, therefore,
inhibiting the infection process. IgNova's technology offers a safe,
economical, and unlimited source of polyclonal antibodies to control
SARS-CoV-2.
The IgY antibody technology has a wide range of applications such
as chewable tablets, sprays, or mouthwash, offering instant
protection against SARS-CoV-2. Additional applications, such as
IgY-coated air filters and masks, could potentially support medical
professionals and other at-risk professions. With antigen and
antibody production as well as specific applications included in the
patent, IgNova envisions an exhaustive IgY technology response to
COVID-19.
"We are at the final research stage," says Michael Gerrits, IgNova
Managing Director, "working closely with scientific institutions and
potential strategic partners to bring the technology to market. We
have started initial testing with the objective to allow our
partners to introduce IgNova technology based products to market in
Q4 2020."
IgNova's patent is based on proprietary IgY technology, a process
that involves immunizing chickens against target pathogens,
extracting antibodies from eggs. IgY technology was developed in the
1980s to help control dental caries. In Japan, the technology is
widely used both in food and human health applications.
"Early research looks promising," says IgNova Managing Director
Tonchy Ugrinovic. "With the right scientific and production
partners, IgNova targets a mass-marketable solution in Q4 of this
year 2020."
About IgNova Founded in 2013, IgNova is a biopharmaceutical R&D start up that
drives IgY technology innovation in accordance with stringent
quality management and design control standards. At production sites
in the US, Japan, and Europe, cutting-edge health and safety
solutions are developed in close collaboration with industry
partners.
Contact Pia Becker Tel: +49 4445 9868174 Mobile: +49 151 10464268 Email: contact@ignova.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
Forrás: OTS Üzleti Sajtószolgálat
MTI © Minden jog fenntartva.
|